Xcout Intel
Epicrispr Biotechnologies competitors & alternatives
The 12 closest competitors and alternatives to Epicrispr Biotechnologies among biotechnology companies — ranked by similarity to what Epicrispr Biotechnologies actually does, not by market-cap band.
Subscribe to see Epicrispr Biotechnologies’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Epicrispr Biotechnologies
Epicrispr Biotechnologies is a pioneering therapeutics company dedicated to developing advanced genetic medicines. The organization focuses on scientific research, platforms, and clinical pipelines to treat serious diseases.
Epicrispr Biotechnologies at a glance
Epicrispr Biotechnologies is a biotechnology company headquartered in United States. It has raised at least $334.8M across the 3 funding rounds on record. Its most recent funding round, Series C, raised $90M in August 2026. Xcout tracks 8 named people at Epicrispr Biotechnologies, including Amber Salzman (Chief Executive Officer).
Epicrispr Biotechnologies leadership
- Amber SalzmanChief Executive Officer
- Amar MuruganChief Legal Officer
- Lei Stanley QiScientific Founder
- Alexandra Collin de l’HortetVice President, Therapeutics
- Benson ChengVice President, Strategy and Operations
- Dipali PatelVice President, Technical Operations
2 more named people on record for Epicrispr Biotechnologies, with roles, board committees and tenure — see the full roster →
Epicrispr Biotechnologies funding rounds
At least $334.8M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $90M | 10 named | |
| Series C | $68M | 10 named | |
| SEC Form D filing | $176.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Epicrispr Biotechnologies news
- FundingPrivate placement (Form D)
Top 12 Epicrispr Biotechnologies competitors
Ranked by semantic similarity — how close each company is to Epicrispr Biotechnologies by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Biotech
EVOPOINT BIOSCIENCES CO., LTD. is an innovation-driven pharmaceutical company that focuses on precision oncology, multi-drug resistant bacterial infections, and metabolic diseases. Utilizing core platforms such as small molecule targeted drug development, complex antibody drug development, and targeted protein degradation, the company researches and develops innovative drug pipelines to provide treatment solutions for patients globally.
Similar biotechnology company
SNIPR Biome is a clinical-stage life sciences company headquartered in Copenhagen, Denmark, pioneering precision medicines and CRISPR-guided technologies for difficult-to-treat conditions.
Similar biotechnology company
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Similar biotechnology company
Arbor Biotechnologies, Inc. is a next-generation gene editing company focused on discovering and developing precise genetic medicines for rare and complex diseases.
Similar biotechnology company
YolTech Therapeutics is a clinical-stage biotechnology company that specializes in developing in vivo gene editing therapies and mRNA drugs for serious diseases. The company utilizes novel CRISPR-Cas enzymes, base editors, and lipid nanoparticle delivery systems to create precision genetic medicines.
Similar biotechnology company
EpimedX LLC is an early-stage biotechnology company based in Oklahoma City, Oklahoma, that is developing novel gene regulation and drug therapies to treat blood diseases such as sickle cell disease, beta-thalassemia, and malaria.
Biotech
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Biotech
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Biotech
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Similar biotechnology company
Hunterian Medicine LLC is a gene-editing company that develops CRISPR-based therapeutics to cure genetic diseases. The company utilizes a patented platform technology with a bidirectional promoter to enable efficient, on-target delivery of CRISPR via a single adeno-associated virus (AAV).
Similar biotechnology company
Excision BioTherapeutics Inc. is a San Francisco-based clinical-stage biotechnology company focused on developing advanced gene editing therapeutics to treat infectious diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Epicrispr Biotechnologies and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Epicrispr Biotechnologiesand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →